Adults aged 18 or over with a diagnosis of hidradenitis suppurativa (HS) for at least 1 year, may qualify to participate. Individuals must have HS

Men and non-pregnant, non-breastfeeding women aged 18 years or older with the intent to undergo treatment (i.e. cheek augmentation) for correction of midface volume deficit,

Individuals aged 2 years and older with a clinical diagnosis of atopic dermatitis (AD), may qualify to participate. Must have moderate to severe disease, with

Adults aged 18 to 65, inclusive, with a clinical diagnosis of moderate-to-severe alopecia areata (AA), defined as the presence of 50% or more and 95%

Adults aged 18 to 75 years (inclusive) with a diagnosis of plaque psoriasis for 24 weeks or more, may qualify for this study. Qualified participants

Adults at least 18 years old with moderate or severe Glabellar Lines (GL) at maximum frown, may qualify to participate in this research trial. These

Individuals aged 12 or older with a clinical diagnosis of nonsegmental vitiligo with depigmented areas, may qualify to participate. Qualified participants must agree to discontinue

Adults at least 18 years of age with a diagnosis of chronic hand eczema (CHE), defined as hand eczema that has persisted for more than

Adults at least 18 years old with moderate or severe Glabellar Lines (GL) at maximum frown, assessed by using the Facial Wrinkle Scale (FWS), may

Adults at least 18 years of age with a diagnosis of hidradenitis suppurativa (HS) for at least 1 year prior to Baseline, may qualify to

Adults aged 18 years or older with a clinical diagnosis of non-segmental vitiligo (bilateral and symmetrical loss of skin pigment), may qualify to participate. Individuals

Adults aged 18 and over diagnosed to have Psoriatic Arthritis (PsA) for at least 3 months in duration, may be eligible for this study. Individuals